255 related articles for article (PubMed ID: 27517317)
21. DDGP followed by radiotherapy vs VIPD followed by radiotherapy in newly diagnosed early NK/T-cell lymphoma.
Zhang L; Shangguan C; Li X; Li L; Wang X; Fu X; Sun Z; Shi Y; Wu J; Zhang X; Yu H; Nan F; Yan J; Chang Y; Zhou Z; Wu X; Feng X; Liu X; Xue H; Zou L; Lu Y; Wang J; Wang G; Li W; Zhang M
Leuk Res; 2022 Jul; 118():106881. PubMed ID: 35688096
[TBL] [Abstract][Full Text] [Related]
22. S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine.
Zhou Z; Li Z; Sun Z; Zhang X; Lu L; Wang Y; Zhang M
Sci Rep; 2016 Mar; 6():23695. PubMed ID: 27021626
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study.
Li JW; Li YJ; Zhong MZ; Liu XL; Li J; Li KL; Liu XY; Zhou F; OuYang Z; Sun ZY; Huang LJ; He JQ; Zhou H; Yi PY
Eur J Haematol; 2018 Mar; 100(3):247-256. PubMed ID: 29194798
[TBL] [Abstract][Full Text] [Related]
24. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
[TBL] [Abstract][Full Text] [Related]
25. A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type.
Ji J; Liu T; Xiang B; Liu W; He C; Chen X; Li J; Chang H; Dai Y; Dong T
Leuk Lymphoma; 2014 Dec; 55(12):2955-7. PubMed ID: 24679007
[No Abstract] [Full Text] [Related]
26. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.
Liang R; Gao GX; Chen JP; Wang JS; Wang XM; Zeng Y; Bai QX; Zhang T; Yang L; Dong BX; Gu HT; Shu MM; Hao CX; Wang JH; Zhang N; Chen XQ
Hematol Oncol; 2017 Dec; 35(4):619-629. PubMed ID: 27723108
[TBL] [Abstract][Full Text] [Related]
27. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up.
Wang L; Wang WD; Xia ZJ; Zhang YJ; Xiang J; Lu Y
Med Oncol; 2014 Mar; 31(3):860. PubMed ID: 24481637
[TBL] [Abstract][Full Text] [Related]
28. Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study.
Wang H; Wuxiao ZJ; Zhu J; Wang Z; Wang KF; Li S; Chen X; Lu Y; Xia ZJ
Leuk Lymphoma; 2015 Apr; 56(4):971-7. PubMed ID: 24991715
[TBL] [Abstract][Full Text] [Related]
29. Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type.
Yang L; Liu H; Xu XH; Wang XF; Huang HM; Shi WY; Jiang SH
Med Oncol; 2013 Dec; 30(4):720. PubMed ID: 24062259
[TBL] [Abstract][Full Text] [Related]
30. Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era.
Qi F; Chen B; Wang J; Lin X; Qi S; Yang J; Zhou S; Wang S; Gui L; Fang H; Liu P; Song Y; Yang S; Li Y; Dong M
Leuk Lymphoma; 2019 Nov; 60(11):2679-2688. PubMed ID: 31298062
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of pegaspargase in extra nodal natural killer/T-cell lymphoma nasal type: A case report from China.
Xiong X; Cai Z; Yang J; Shu X
J Cancer Res Ther; 2015; 11(3):665. PubMed ID: 26458696
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
[TBL] [Abstract][Full Text] [Related]
33. Treatment and Prognosis of Newly Diagnosed Advanced-Stage Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Real-World Study across Two Decades.
Wei YC; Qi F; Chen B; Zhang CG; Fang H; Zhang D; Qi SN; Chai Y; Li YX; Dong M
Chemotherapy; 2024; 69(2):108-121. PubMed ID: 37984344
[TBL] [Abstract][Full Text] [Related]
34. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.
Ding H; Chang J; Liu LG; Hu D; Zhang WH; Yan Y; Ma LY; Li ZC; Ma YJ; Hao SG; Tao R
Int J Hematol; 2015 Aug; 102(2):181-7. PubMed ID: 25997870
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China.
Zhang Y; Zhang W; Li J; Duan M; Han B; Zhu T; Zhuang J; Cai H; Cao X; Chen M; Zhou D
Ann Hematol; 2019 Jan; 98(1):143-150. PubMed ID: 30209556
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma.
Ahn HK; Kim SJ; Hwang DW; Ko YH; Tang T; Lim ST; Kim WS
Invest New Drugs; 2013 Apr; 31(2):469-72. PubMed ID: 23108598
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III-IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus.
Zhao Q; Fan S; Chang Y; Liu X; Li W; Ma Q; Li Y; Wang Y; Zhang L; Zhang M
Cancer Manag Res; 2019; 11():3555-3564. PubMed ID: 31118779
[No Abstract] [Full Text] [Related]
38. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers.
Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of patients treated with SVILE
Wei L; Yang L; Ye J; Cong J; Li X; Yao N; Yang J; Cui X; Ding J; Wu Y; Wang J
Cancer Biol Med; 2020 Aug; 17(3):795-804. PubMed ID: 32944407
[No Abstract] [Full Text] [Related]
40. GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Wang JJ; Dong M; He XH; Li YX; Wang WH; Liu P; Yang JL; Gui L; Zhang CG; Yang S; Zhou SY; Shi YK
Medicine (Baltimore); 2016 Feb; 95(6):e2787. PubMed ID: 26871836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
